ClinicalTrials.gg
RecruitingNCT07866131Updated Oct 8, 2026

Observational Assessment of Skin Appearance Changes During PRX S Cosmetic Treatment in Participants With Acne-Prone Skin

An interventional study of PRX S topical cosmetic treatment and WiQo home care regimen (Nourishing Cream; Balancing Cream) in Acne-prone Skin and Skin Disease, sponsored by WiQo S.p.A.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by WiQo S.p.A. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 8, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 202 studies in Skin Diseases with a site in United States — 32 open to participants now, 49 under way, 9 of them phase 3. Skin Diseases · United States.

Planned enrollment
124th of 172
30 · median 99
Started
2026
with 10 others
No phase
33 of 202
6 open now
Primary completion
2026-12
later than 14 of 48 live
Registered
202nd of 202
by date

Among the 202 studies in Skin Diseases with a site in United States, this one is the 124th largest by planned enrollment of the 172 interventional ones that give a count, is one of 11 that started in 2026, is one of 33 with no phase, reaches primary completion later than 14 of the 48 other live ones, and was the 202nd registered.

Skin Diseases

497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.

Browse Skin Diseases studies →

Open to participants now

32 of the 202 studies in Skin Diseases with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Skin Diseases with a site in United States, or all of them as a file.
02

Study summary

This pilot cohort study evaluates changes in skin surface appearance in adult participants with acne-prone skin during and following a standardized five-session course of PRX S (WiQo SpA), a topical cosmetic product designed for oily and acne-prone skin.

The study asks whether a standardized in-office PRX S treatment cycle - five sessions administered at two-week intervals and complemented by a prescribed home care regimen - is associated with observable changes in objective skin surface parameters (pore appearance, texture, spots, redness, porphyrins), clinician-rated acne severity (IGA, GAGS), and participant-reported skin-related quality of life (QoL-RA) in adults with acne-prone skin.

Using a single-group, pre-post observational design across two U.S. sites (Leawood, KS and Tulsa, OK), 30 participants will undergo VISIA complexion analysis and clinical assessments at baseline (T0), mid-cycle (T1, Week 6), and end of follow-up (T2, Week 10). No single primary endpoint is designated; all analyses are explicitly exploratory.

03

Conditions studied

  • Acne-prone Skin
  • Skin Disease

Browse trials for

Keywords

  • acne-prone skin
  • skin condition
  • cosmetics
  • pore refinement
  • quantitative evaluation
  • quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older at the time of .
  • Presence of acne-prone skin characteristics defined as an IGA score of 1 (almost clear) to 3 (moderate) at baseline (T0).
  • Willing and able to commit to 5 in-office treatment sessions at approximately 2-week intervals over approximately 8 weeks, plus one follow-up visit at Week 10.
  • Willing to discontinue all current skincare products and adhere exclusively to the WiQo standardized home care regimen throughout the study period. The participant's current skincare regimen must be, in the investigator's judgment, safe to discontinue on the day of the first treatment session without requiring a prior .
  • Able to understand and willing to sign the informed consent form prior to any study procedure.
  • In general good health as determined by medical history and investigator judgment.
  • Ability to read and understand English at a level sufficient to provide written informed consent and complete all study questionnaires independently.

Exclusion criteria

Exclusion Criteria:

  • IGA score of 0 (clear) or 4 (severe) at baseline.
  • Active skin infection, open wounds, or acute inflammatory dermatological conditions in the facial treatment area at the time of enrollment.
  • History of or known allergy to any component of the PRX S formulation or the WiQo home care products.
  • Use of systemic retinoids within 6 months prior to enrollment.
  • Use of systemic antibiotics for acne within 4 weeks prior to enrollment.
  • Ongoing use of topical prescription acne medications (retinoids, topical antibiotics, dapsone) that the participant is unwilling or unable to discontinue.
  • Pregnancy, breastfeeding, or planned pregnancy during the study period. Pregnancy status is determined by participant self-report at screening and confirmed through the signed Form, in which the participant acknowledges that pregnancy constitutes a to the study treatment.
  • Prior cosmetic or aesthetic treatment of the face (chemical peel, laser, microneedling, injectables) within 4 weeks prior to enrollment, or prior treatment of the chest or back within 4 weeks prior to enrollment that, in the investigator's judgment, could confound GAGS assessments.
  • Any active medical condition that, in the investigator's judgment, could confound study assessments or place the participant at undue risk.
  • Participation in another interventional clinical study within 30 days prior to enrollment.
  • Inability or unwillingness to comply with study procedures and follow-up requirements.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    PRX S Cosmetic Treatment with Home Care Regimen

    Other: PRX S topical cosmetic treatment · Other: WiQo home care regimen (Nourishing Cream; Balancing Cream)

Interventions

  • OtherPRX S topical cosmetic treatment

    PRX S (WiQo SpA, Milan, Italy) is a topical cosmetic formulation designed for acne-prone and oily skin. It is applied in-office by trained aesthetic professionals or dermatologists using a proprietary non-ablative technique with no visible peeling or downtime. Five sessions are administered at two-week intervals (Weeks 0, 2, 4, 6, 8). The application procedure is adapted to the participant's skin presentation: Procedure 1 for oily skin with enlarged pores; Procedure 2 for comedone-predominant presentations. PRX S is supplied directly to study sites by the Sponsor free of charge.

  • OtherWiQo home care regimen (Nourishing Cream; Balancing Cream)

    A standardized daily home care regimen prescribed in conjunction with in-office PRX S sessions, consisting of two commercially available cosmetic products supplied by the Sponsor: WiQo Nourishing Cream for Normal and Combination Skin (applied each morning) and WiQo Balancing Cream (applied each evening). The Balancing Cream contains micronized azelaic acid, encapsulated salicylic acid, fermented botanical extracts, and niacinamide. Both products are supplied to participants free of charge for the duration of the study.

06

What researchers measure

Primary outcomes

  1. Change in VISIA Pores Score

    Objective pore assessment performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ). The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate fewer visible pores relative to the reference population and represent a better outcome.

    Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)

  2. Change in VISIA Spots Score

    Objective spot assessment performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ). The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate fewer visible spots relative to the reference population and represent a better outcome.

    Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)

  3. Change in VISIA Red Areas Score

    Objective assessment of red area extent performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ) using RBX® Red channel imaging. The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate reduced surface redness relative to the reference population and represent a better outcome.

    Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)

  4. Change in VISIA Porphyrins Score

    Objective porphyrin assessment performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ) using UV fluorescence photography. The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate fewer porphyrins relative to the reference population and represent a better outcome.

    Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)

  5. Change in VISIA Texture Score

    Objective skin texture assessment performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ). The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate smoother skin texture relative to the reference population and represent a better outcome.

    Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)

Secondary outcomes

  1. Change in Investigator Global Assessment (IGA) Score

    Clinician-rated acne severity assessed using the Investigator Global Assessment (IGA) scale, a 5-point ordinal scale ranging from 0 to 4 (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe). Lower scores indicate less severe acne and represent a better outcome. The T0 value serves as individual reference.

    Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)

  2. Change in Global Acne Grading System (GAGS) Score

    Clinician-rated acne severity assessed using the Global Acne Grading System (GAGS), a weighted scoring instrument that evaluates acne lesion type and distribution across six facial and truncal regions (forehead, right cheek, left cheek, nose, chin, and chest/back). Total scores range from 0 to 44: 0 = no acne; 1-18 = mild; 19-30 = moderate; 31-38 = severe; \>38 = very severe. Lower scores indicate less severe acne and represent a better outcome. The T0 value serves as individual reference.

    Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)

  3. Change in Quality of Life Relevance-Acne (QoL-RA) Score

    Participant-reported acne-related quality of life assessed using the Quality of Life Relevance-Acne (QoL-RA) questionnaire (Chernyshov et al., JAAD International, 2024). The QoL-RA is a 19-item self-reported instrument covering 3 dimensions: Socioemotional (11 items), Symptoms (4 items), and Stigma and Suicidal thoughts (4 items). Each item is rated on a 4-point scale (0 = Never; 1 = Rarely; 2 = Sometimes; 3 = Frequently); total scores range from 0 to 57. Higher scores indicate greater HRQoL impairment and represent a worse outcome.

    Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)

  4. Treatment Tolerability

    Incidence and type of adverse events and product-related tolerability findings across all 5 treatment sessions.

    Time frame: Through study completion (Week 10)

Other outcomes

  1. VISIA Acne-Prone Skin Composite Index (VISIA-APS)

    Pre-specified composite summary index computed as the mean of the z-scores of the five principal VISIA parameters (pores, spots, red areas, porphyrins, and texture), standardized using the sample mean and SD at baseline (T0). The direction of each z-score is pre-specified so that positive values consistently indicate improvement. The VISIA-APS has no fixed minimum or maximum; higher values indicate greater overall improvement across all five acne-prone skin parameters and represent a better outcome.

    Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)

  2. VISIA Wrinkles Score

    Objective wrinkle assessment performed by VISIA Complexion Analysis system (Canfield Scientific, Parsippany, NJ). The score is a normalized index relative to an age- and phototype-matched reference population. Lower scores indicate fewer visible wrinkles relative to the reference population. This parameter is reported descriptively only and is not included in formal inferential analyses.

    Time frame: Baseline (T0, Week 0), mid-cycle (T1, Week 6), end of follow-up (T2, Week 10)

07

Study locations

2 of 2 sites recruiting
  • Regain Functional Medicine and Aesthetics
    Leawood, Kansas 66211, United States
    Recruiting
  • VibrantSkin Dermatology and Laser
    Tulsa, Oklahoma 74137, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. All data collected in this study are proprietary to the Sponsor (WiQo SpA) and are subject to applicable data privacy and protection regulations, including the EU General Data Protection Regulation (GDPR) and applicable U.S. state privacy laws. No IPD sharing is planned.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.

Of 53 industry-sponsored interventional studies with no phase under Skin Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 3 months is close to that.

Counting every sponsor, half of 95 studies reached it within 7 months; a quarter within 2 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 8, 2026
StartActual
Sep 21, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07866131
Lead sponsor
WiQo S.p.A.
Collaborators
Mathsly Research
Responsible party
Sponsor
First posted
Oct 8, 2026
Start date
Sep 21, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

Deborah Subissati
Contact
deborah.subissati@wiqo.eu
+39 040360408
Maria Luisa Garo
Contact
marilu.garo@mathsly.it
+393774326165
Maria Luisa Garo
study director · Mathsly Research
Kathy Gaumer, MD
principal investigator · Regain Functional Medicine and Aesthetics, Leawood, KS
Kesha Buster, MD
principal investigator · VibrantSkin Dermatology and Laser, Tulsa, OK
Deborah Subissati
study chair · WiQo S.p.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion